SciClone Discloses Tentative $12.8 Million SEC Settlement over FCPA allegations

Under the terms of the proposed agreement, which has yet to be approved by the agency’s commissioners, the California-based drug manufacturer would pay a $2.5 million civil penalty, without having to admit or deny any wrongdoing.

Unlock unlimited access to all Global Investigations Review content